Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells.

Stanniocalcin-1 (STC1) is an endocrine hormone originally discovered in the corpuscles of Stannius, endocrine glands on kidneys of bony fishes, and also has been identified in mammals. The mammalian STC1 gene is widely expressed in various tissues and appears to be involved in diverse biological processes. There is growing evidence to suggest that altered patterns of gene expression have a role in human cancer development. Recently STC1 has been identified as a stimulator of mitochondrial respiration and has been hypothesized to be functionally related to the Warburg effect, of which hypoxia-inducible factor (HIF)-1 plays a key role in reprogramming tumor metabolism. This prompted us to examine the involvement of HIF-1 in the regulation of STC1 expression in tumor hypoxia. Our data reveal that hypoxia can stimulate STC1 gene expression in various human cancer cell lines, including those derived from colon carcinomas, nasopharyngeal cancer (CNE-2, HONE-1, HK-1), and ovarian cancer (CaOV3, OVCAR3, SKOV3). By far, the greatest response was observed in CNE-2 cells. In further studies on CNE-2 cells, desferrioxamine, cobalt chloride, and O(2) depletion all increased HIF-1alpha protein and STC1 mRNA levels. Desferrioxamine treatment, when coupled with Fe replenishment, abolished these effects. RNA interference studies further confirmed that endogenous HIF-1alpha was a key factor in hypoxia-induced STC1 expression. The ability of vascular endothelial growth factor to stimulate STC1 expression in CNE-2 cells was comparatively low. Collectively, the present findings provide the first evidence of HIF-1 regulation of STC1 expression in human cancer cells. The studies have implications as to the role of STC1 in hypoxia induced adaptive responses in tumor cells.

[1]  G. Semenza,et al.  Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. , 2005, Blood.

[2]  P. Munson,et al.  Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. , 2004, Endocrine-related cancer.

[3]  D. Richardson,et al.  Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. , 2004, Blood.

[4]  A. Giatromanolaki,et al.  Tumour angiogenesis: vascular growth and survival , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[5]  A. Fienberg,et al.  Characterization of Stanniocalcin 2, a Novel Target of the Mammalian Unfolded Protein Response with Cytoprotective Properties , 2004, Neurobiology of Aging.

[6]  G. F. Wagner,et al.  Co-localization of stanniocalcin-1 ligand and receptor in human breast carcinomas , 2004, Molecular and Cellular Endocrinology.

[7]  I. Zachary,et al.  Vascular Endothelial Growth Factor–Regulated Gene Expression in Endothelial Cells: KDR-Mediated Induction of Egr3 and the Related Nuclear Receptors Nur77, Nurr1, and Nor1 , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[8]  D. Richardson,et al.  The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. , 2003, Carcinogenesis.

[9]  R. Reddel,et al.  Mammalian stanniocalcins and cancer. , 2003, Endocrine-related cancer.

[10]  G. Thakker,et al.  Analysis of VEGF-responsive Genes Involved in the activation of endothelial cells , 2003, Molecular Cancer.

[11]  A. Giuliano,et al.  Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  D. Richardson,et al.  Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  D. Richardson,et al.  The role of iron in cell cycle progression and the proliferation of neoplastic cells. , 2002, Biochimica et biophysica acta.

[14]  G. F. Wagner,et al.  Stanniocalcin 1 alters muscle and bone structure and function in transgenic mice. , 2002, Endocrinology.

[15]  W. Kühnel,et al.  Preferential Topography of Proteins Regulating Vascularization and Apoptosis in a MX1 Xenotransplant After Treatment With Hypoxia, Hyperthermia, Ifosfamide, and Irradiation , 2002, American journal of clinical oncology.

[16]  Franklin Peale,et al.  In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. , 2002, Physiological genomics.

[17]  M. Ichihara,et al.  Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. , 2002, The American journal of pathology.

[18]  M. King,et al.  BRCA1 transcriptionally regulates genes involved in breast tumorigenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Gassmann,et al.  Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. , 2002, Cancer research.

[20]  G. F. Wagner,et al.  Overexpression of human stanniocalcin affects growth and reproduction in transgenic mice. , 2002, Endocrinology.

[21]  Melissa C Southey,et al.  Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. , 2002, Cancer research.

[22]  K. Ishibashi,et al.  Prospect of a stanniocalcin endocrine/paracrine system in mammals. , 2002, American journal of physiology. Renal physiology.

[23]  R. Strausberg,et al.  Transcriptional response to hypoxia in human tumors. , 2001, Journal of the National Cancer Institute.

[24]  M. Asaka,et al.  Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. , 2001, Cancer research.

[25]  J. Orenstein,et al.  Requirement for Transforming Growth Factor β1 in Controlling T Cell Apoptosis , 2001, The Journal of experimental medicine.

[26]  S. Maxwell,et al.  Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. , 2001, Journal of cell science.

[27]  D. Richardson.  The controversial role of deferiprone in the treatment of thalassemia. , 2001, The Journal of laboratory and clinical medicine.

[28]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[29]  T. Tsunoda,et al.  Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. , 2001, Cancer research.

[30]  R. L. Baldwin,et al.  Differential gene expression between normal and tumor-derived ovarian epithelial cells. , 2000, Cancer research.

[31]  F. Peale,et al.  Gene expression profiling in an in vitro model of angiogenesis. , 2000, The American journal of pathology.

[32]  M. Gassmann,et al.  Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. , 2000, Molecular endocrinology.

[33]  M. Monden,et al.  Assessment of Stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers. , 2000, International journal of oncology.

[34]  M. Kaste,et al.  Stanniocalcin: A molecular guard of neurons during cerebral ischemia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  E. Cadenas,et al.  Analysis of the pathways of nitric oxide utilization in mitochondria , 2000, Free radical research.

[36]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[37]  D. Richardson,et al.  The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. , 1999, Blood.

[38]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[39]  G. F. Wagner,et al.  Comparative Analysis of Mammalian Stanniocalcin Genes* *This work was supported by grants from London Health Sciences Research, Inc. (to G.E.D.), the London Regional Cancer Center (to G.E.D.), and the Medical Research Council of Canada (to G.F.W.). , 1998, Endocrinology.

[40]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[41]  L. Huang,et al.  Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .

[42]  Y. Fujii‐Kuriyama,et al.  Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Richardson,et al.  Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. , 1998, The Journal of laboratory and clinical medicine.

[44]  R. Reddel,et al.  Human stanniocalcin (STC): genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats. , 1998, Genomics.

[45]  G. F. Wagner,et al.  Comparative analysis of mammalian stanniocalcin genes. , 1998, Endocrinology.

[46]  G. Semenza,et al.  V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. , 1997, Cancer research.

[47]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C. Cooper,et al.  The Relationship of Intracellular Iron Chelation to the Inhibition and Regeneration of Human Ribonucleotide Reductase* , 1996, The Journal of Biological Chemistry.

[49]  M. Knowles,et al.  Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. , 1996, Oncogene.

[50]  G. F. Wagner,et al.  Human stanniocalcin: a possible hormonal regulator of mineral metabolism. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  P. Troncoso,et al.  Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. , 1995, Oncogene.

[52]  D. Jong,et al.  A novel human cDNA highly homologous to the fish hormone stanniocalcin , 1995, Molecular and Cellular Endocrinology.

[53]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Sandvik,et al.  Regulation of protein synthesis in human cells exposed to extreme hypoxia. , 1995, Anticancer research.

[55]  F. Bosman,et al.  Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. , 1994, Cancer research.

[56]  J Lucas,et al.  Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. , 1993, Cancer research.

[57]  Y. Nakamura,et al.  Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. , 1993, Cancer research.

[58]  Y. Nakamura,et al.  Frequent multiplication of the long arm of chromosome 8 in hepatocellular carcinoma. , 1993, Cancer research.

[59]  K. Keyomarsi,et al.  Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells. , 1992, Cancer research.

[60]  G. F. Wagner,et al.  Purification, characterization, and bioassay of teleocalcin, a glycoprotein from salmon corpuscles of Stannius. , 1986, General and comparative endocrinology.

[61]  E. Pettersen,et al.  Regulation of protein metabolism of human cells during and after acute hypoxia. , 1986, Cancer research.

[62]  F. L. Hoch.  Thyroid hormone action on mitochondria , 1976, Journal of bioenergetics and biomembranes.